Menu

Notable Science Quotes

Eugene Garfield, the cancer moonshot, employee genetic testing, and more

Apr 1, 2017
The Scientist Staff

Eugene Garfield: 1925–2017ILLUSTRATION BY ERICA P. JOHNSON

Everything he did, he was ahead of everybody in so many ways. He was a genius of a very special type. Not only because he had this incredible imagination and brain, but he had incredible tenacity and courage.

—Vitek Tracz, publisher of Faculty of 1000 and former co-owner of The Scientist, on the passing of Eugene Garfield, the scientometrics pioneer who launched The Scientist in 1986 (February 27)

 

I think that measuring with precision human activity on the climate is something very challenging to do, and there’s tremendous disagreement about the degree of impact, so no, I would not agree that it’s a primary contributor to the global warming that we see.

Newly confirmed US Environmental Protection Agency Administrator Scott Pruitt, on the CNBC program Squawk Box (March 9)

 

It is my hope that this new administration, once it gets organized—and I’m not being facetious—can be as committed and enthusiastic as we were. The only bipartisan thing left in America is the fight against cancer.

Former Vice President Joe Biden, in a speech delivered at this year’s South by Southwest festival in Austin, Texas, about the federal government’s role in cancer research (March 12)

 

To succeed, the Trump administration needs to assume the leadership Biden was given previously as vice president to foster cooperation and collaboration among the various federal agencies and institutions with relevant resources, and to guide [the] moonshot in a direction that maximizes its value to public health.

—Nancy Brinker, founder of the Susan G. Komen breast cancer charity, and journalist Eric Rosenthal, writing in The Hill about how Donald Trump should pursue Barack Obama’s cancer “moonshot” (February 15)

 

His treatment was much easier than what some people have to endure, but I’ve found that physicians who have a cancer experience understand the human side of things and how treatment impacts individuals and families.

—Shelley Fuld Nasso, CEO of the National Coalition for Cancer Survivorship, talking about Donald Trump’s appointment of  Scott Gottlieb— a physician, drug industry financier, and cancer survivor—to lead the US Food and Drug Administration (March 10)

 

It would allow employers to ask employees invasive questions about . . . genetic tests they and their families have undergone . . . [and] to impose stiff financial penalties on employees who choose to keep such information private, thus empowering employers to coerce their employees.

—Nancy Cox, president of the American Society of Human Genetics, in a letter delivered to the House Committee on Education and the Workforce a day before it approved HR 1313, a bill that would allow companies to require their workers to undergo genetic testing or pay fines (March 10)

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.